In an update of the 19,490-patient Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention, both raloxifene and tamoxifen remain effective options to prevent breast cancer at 81 months of follow-up. Raloxifene improved its effectiveness against noninvasive breast cancer, caused significantly less endometrial cancer and was significantly less toxic than tamoxifen...
More...